Trends & Forecasts

The first US biosimilar has been pocketed and the game is on. We bring six experts to the table to discuss the impact on industry dynamics.

Without proper supply chain management, efforts to supply drugs to the developing world are wasted.

$100 million pledged to kick start investment in new research

New technology interprets slang and banter to find out what people really think

Global healthcare company GlaxoSmithKline (GSK) has pledged to be carbon neutral by 2050.

Pushing for cleaner, greener manufacturing is not only good for the planet, it’s great for business.

Sitting Down With… James Christie, Project Director for Manufacturing, Association of the British Pharmaceutical Industry (ABPI), London, UK.

Only you have the answer. Nominate now.

Could the Pfizer–Hospira deal be a stepping stone to a company split?

Research into rare diseases is on the rise, but are prices sustainable?